Ratio Therapeutics Stock

Ratio Therapeutics is a clinical phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.

Sign up today and learn more about Ratio Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Ratio Therapeutics Stock

Ratio Therapeutics develops radiotherapeutics for the treatment of cancers. They engaged in research and development platforms, trillium and macropa, enable the imaging, discovery, and advancement of radiopharmaceuticals. It enables doctors to detect a wide range of epithelial-derived cancers, such as breast, pancreatic, lung, colon cancers, and more.

Funding History

June 2022$20.0M
February 2023$20.0M


Chief Data Officer

Jacob Hesterman


Reed Malleck


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: